2 2 Appledown Clinical Research Limited 03886155 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is clinical research. Digita Accounts Production Advanced 6.30.9574.0 true 03886155 2024-04-01 2025-03-31 03886155 2025-03-31 03886155 core:CurrentFinancialInstruments 2025-03-31 03886155 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 03886155 core:Non-currentFinancialInstruments 2025-03-31 03886155 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 03886155 core:FurnitureFittingsToolsEquipment 2025-03-31 03886155 bus:SmallEntities 2024-04-01 2025-03-31 03886155 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 03886155 bus:FilletedAccounts 2024-04-01 2025-03-31 03886155 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 03886155 bus:RegisteredOffice 2024-04-01 2025-03-31 03886155 bus:Director1 2024-04-01 2025-03-31 03886155 bus:Director2 2024-04-01 2025-03-31 03886155 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 03886155 bus:Agent1 2024-04-01 2025-03-31 03886155 core:FurnitureFittings 2024-04-01 2025-03-31 03886155 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 03886155 core:OfficeEquipment 2024-04-01 2025-03-31 03886155 countries:EnglandWales 2024-04-01 2025-03-31 03886155 2024-03-31 03886155 core:FurnitureFittingsToolsEquipment 2024-03-31 03886155 2023-04-01 2024-03-31 03886155 2024-03-31 03886155 core:CurrentFinancialInstruments 2024-03-31 03886155 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 03886155 core:Non-currentFinancialInstruments 2024-03-31 03886155 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 03886155 core:FurnitureFittingsToolsEquipment 2024-03-31 xbrli:pure iso4217:GBP

Registration number: 03886155

Appledown Clinical Research Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Appledown Clinical Research Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Financial Statements

4 to 8

 

Appledown Clinical Research Limited

Company Information

Directors

Mr D McKenna

Mrs CJ McKenna

Registered office

Fawley House
2 Regatta Place Marlow Road
Bourne End
Bucks
SL8 5TD

Accountants

Sterling Grove Accountants Limited
Chartered Certified AccountantsFawley House
2 Regatta Place
Marlow Road
Bourne End
Buckinghamshire
SL8 5TD

 

Appledown Clinical Research Limited

(Registration number: 03886155)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

3,120

1,822

Current assets

 

Debtors

5

62,022

46,816

Cash at bank and in hand

 

36,282

42,145

 

98,304

88,961

Creditors: Amounts falling due within one year

6

(72,557)

(68,232)

Net current assets

 

25,747

20,729

Total assets less current liabilities

 

28,867

22,551

Creditors: Amounts falling due after more than one year

6

(1,000)

(7,000)

Provisions for liabilities

(780)

(346)

Net assets

 

27,087

15,205

Capital and reserves

 

Called up share capital

100

100

Retained earnings

26,987

15,105

Shareholders' funds

 

27,087

15,205

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

 

Appledown Clinical Research Limited

(Registration number: 03886155)
Balance Sheet as at 31 March 2025

Approved and authorised by the Board on 1 July 2025 and signed on its behalf by:
 

.........................................
Mr D McKenna
Director

.........................................
Mrs CJ McKenna
Director

 

Appledown Clinical Research Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Fawley House
2 Regatta Place Marlow Road
Bourne End
Bucks
SL8 5TD
United Kingdom

These financial statements were authorised for issue by the Board on 1 July 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

Government grants

Government grants are recognised under the accrual model of grant recognition. This model requires the grant to be classified as either a revenue-based grant or a capital-based grant.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the entity recognises expenses for the related costs for which the grants are intended to compensate.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Appledown Clinical Research Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixture and fittings

15% on reducing balance

Office equipment

33% on reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised at the transaction price, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Trade creditors are recognised at the transaction price.

 

Appledown Clinical Research Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Appledown Clinical Research Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 2).

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2024

20,750

20,750

Additions

1,966

1,966

At 31 March 2025

22,716

22,716

Depreciation

At 1 April 2024

18,928

18,928

Charge for the year

668

668

At 31 March 2025

19,596

19,596

Carrying amount

At 31 March 2025

3,120

3,120

At 31 March 2024

1,822

1,822

5

Debtors

Current

2025
£

2024
£

Trade debtors

61,561

46,176

Prepayments

461

587

Other debtors

-

53

 

62,022

46,816

 

Appledown Clinical Research Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

6

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

7

6,000

6,000

Trade creditors

 

37,748

32,070

Taxation and social security

 

27,579

17,287

Accruals and deferred income

 

863

863

Other creditors

 

367

12,012

 

72,557

68,232

Creditors: amounts falling due after more than one year

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

7

1,000

7,000

7

Loans and borrowings

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

1,000

7,000

Current loans and borrowings

2025
£

2024
£

Bank borrowings

6,000

6,000